The Three Pillars of Cardiovascular Advancement
How technology, innovation, and preventive care drove the last 10 years of improved public heart health.
Related Articles
Cardiology Month in Review: September 2024
The HCPLive Cardiology month in review for September 2024 spotlights ESC Congress 2024, Family Heart Global Summit, pipeline updates, and more!
Social Determinants of Health Impact Sickle Cell Disease Mortality in US
An elevated social vulnerability index score was linked to increased mortality among patients with SCD in the 5-year CDC WONDER database.
Hidradenitis Suppurativa Does Not Increase Female Infertility Risk, Study Finds
Contrary to previous research, findings suggest no significant difference in infertility between patients with HS, other dermatological diseases, and healthy controls.
Triptans Prove to be More Effective for Migraines Than Newer Drugs
Triptans, including eletriptan and sumatriptan, offer better migraine relief than newer, more expensive drugs, suggesting they should be first-line treatments.
Matched Analysis Finds No Link Between Dupilumab Use and Adverse Pregnancy Outcomes
An EADV 2024 study suggests dupilumab use during pregnancy is generally safe and may lower risks of preterm labor, gestational hypertension, and diabetes.
Aldeyra Resubmits New Drug Application for Reproxalap for Dry Eye Disease
The resubmission includes positive data from a recently completed dry eye disease symptom trial requested by the FDA after a review of the previous NDA.
FDA Approves Exact Sciences’ Cologuard Plus Test for Colorectal Cancer Screening
The approval is based on findings from BLUE-C, where Cologuard Plus demonstrated sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at…
Complete Psoriasis Clearance at Year 1 Sustained to Year 4 for Majority on Bimekizumab
These data were presented at EADV 2024 by UCB, with presenters highlighting positive long-term efficacy findings for bimekizumab among patients with plaque psoriasis.
Crisugabalin Provides Significant Pain Improvements in Adults with Postherpetic Neuralgia
Crisugabalin at 40 mg/d or 80 mg/d significantly reduced daily pain in adults with postherpetic neuralgia, a phase 3 study found.
Dupilumab Improves Sleep, Itch, and Other QoL Measures in Children With Eczema
A new post-hoc analysis has also revealed improvements in quality of life in patients’ caregivers.